Health Catalyst Inc (HCAT)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $115.00M
Last updated: Nov 17, 2026 at 11:05 AM ET
Health Catalyst Inc (HCAT) Earnings: Report Dates and Results
Health Catalyst (HCAT) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Health Catalyst reported EPS of -$0.08, below the -$0.07 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HCAT has an expected report date of Mar 10, 2027.
HCAT Earnings Call
The latest HCAT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, HCAT beat 23 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $56.28M, down 26.3% from $76.32M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.08 | -$0.07 | -$0.07 - -$0.02 | -14.29% | Miss | -233.3% | 4 | 0 up, 3 down | Nov 5, 2026 | $56.28M |
| Jun 30, 2026 | -$0.08 | -$0.05 | N/A | -60.00% | Miss | N/A | 3 | 2 up, 1 down | Aug 6, 2026 | $70.49M |
| Mar 31, 2026 | $0.02 | $0.01 | -$0.01 - $0.05 | +100.00% | Beat | +100.0% | 5 | 0 up, 5 down | May 11, 2026 | $70.76M |
| Dec 31, 2025 | $0.08 | $0.10 | $0.07 - $0.15 | -16.14% | Miss | +100.0% | 7 | 0 up, 2 down | Mar 12, 2026 | $74.68M |
| Sep 30, 2025 | $0.06 | $0.07 | $0.04 - $0.09 | -14.29% | Miss | -14.3% | 8 | 1 up, 6 down | Nov 10, 2025 | $76.32M |
| Jun 30, 2025 | -$0.08 | -$0.09 | N/A | +11.11% | Beat | -166.7% | 9 | 0 up, 9 down | Aug 7, 2025 | $80.72M |
| Mar 31, 2025 | $0.01 | $0.03 | -$0.01 - $0.04 | -66.67% | Miss | -80.0% | 9 | 0 up, 2 down | May 7, 2025 | $79.41M |
| Dec 31, 2024 | $0.04 | $0.08 | $0.03 - $0.15 | -47.64% | Miss | +100.0% | 11 | 3 up, 1 down | Feb 26, 2025 | $79.61M |
| Sep 30, 2024 | $0.07 | $0.09 | $0.05 - $0.16 | -22.22% | Miss | +133.3% | 13 | 0 up, 0 down | Nov 6, 2024 | $76.35M |
| Jun 30, 2024 | $0.12 | $0.08 | $0.05 - $0.13 | +50.00% | Beat | +140.0% | 13 | 0 up, 0 down | Aug 7, 2024 | $75.90M |
| Mar 31, 2024 | $0.05 | $0.03 | -$0.06 - $0.06 | +66.67% | Beat | 0.0% | 14 | 0 up, 0 down | May 9, 2024 | $74.72M |
| Dec 31, 2023 | $0.02 | -$0.01 | -$0.11 - $0.02 | +300.00% | Beat | N/A | 13 | 1 up, 0 down | Feb 22, 2024 | $75.08M |
| Sep 30, 2023 | $0.03 | -$0.01 | -$0.13 - $0.05 | +400.00% | Beat | N/A | 12 | 0 up, 0 down | Nov 2, 2023 | $73.77M |
| Jun 30, 2023 | $0.05 | -$0.01 | -$0.12 - $0.12 | +600.00% | Beat | N/A | 14 | 0 up, 0 down | Aug 8, 2023 | $73.21M |
| Mar 31, 2023 | $0.05 | -$0.04 | -$0.12 - $0.02 | +225.00% | Beat | N/A | 13 | 0 up, 0 down | May 9, 2023 | $73.87M |
| Dec 31, 2022 | -$0.05 | -$0.11 | -$0.29 - $0.00 | +54.55% | Beat | N/A | 12 | 0 up, 0 down | Feb 28, 2023 | $69.16M |
| Sep 30, 2022 | -$0.13 | -$0.19 | -$0.35 - -$0.11 | +31.58% | Beat | N/A | 13 | 1 up, 0 down | Nov 8, 2022 | $68.35M |
| Jun 30, 2022 | -$0.03 | -$0.09 | -$0.27 - -$0.01 | +66.67% | Beat | N/A | 12 | 0 up, 0 down | Aug 4, 2022 | $70.63M |
| Mar 31, 2022 | -$0.06 | -$0.11 | -$0.30 - -$0.01 | +45.45% | Beat | N/A | 11 | 0 up, 0 down | May 10, 2022 | $68.09M |
| Dec 31, 2021 | -$0.19 | -$0.21 | -$0.44 - -$0.07 | +9.52% | Beat | N/A | 13 | N/A | Mar 1, 2022 | $64.72M |
| Sep 30, 2021 | -$0.18 | -$0.22 | -$0.36 - -$0.17 | +18.18% | Beat | N/A | 11 | N/A | Nov 9, 2021 | $61.74M |
| Jun 30, 2021 | $0.00 | -$0.14 | -$0.28 - -$0.03 | +98.79% | Beat | N/A | 10 | N/A | Aug 5, 2021 | $59.63M |
| Mar 31, 2021 | -$0.06 | -$0.14 | -$0.25 - -$0.03 | +57.14% | Beat | N/A | 11 | N/A | May 6, 2021 | $55.85M |
| Dec 31, 2020 | -$0.16 | -$0.19 | -$0.27 - -$0.12 | +15.79% | Beat | N/A | 12 | N/A | Feb 25, 2021 | $53.28M |
| Sep 30, 2020 | -$0.21 | -$0.27 | -$0.32 - -$0.22 | +22.22% | Beat | N/A | 13 | N/A | Nov 10, 2020 | $47.19M |
| Jun 30, 2020 | -$0.15 | -$0.22 | -$0.31 - -$0.15 | +31.82% | Beat | N/A | 13 | N/A | Aug 11, 2020 | $43.26M |
| Mar 31, 2020 | -$0.16 | -$0.26 | -$0.31 - -$0.21 | +38.46% | Beat | N/A | 9 | N/A | May 12, 2020 | $45.12M |
| Dec 31, 2019 | -$0.21 | -$0.29 | -$0.33 - -$0.21 | +27.59% | Beat | N/A | 7 | N/A | Feb 27, 2020 | $43.50M |
| Sep 30, 2019 | -$0.27 | -$0.37 | -$0.41 - -$0.34 | +27.03% | Beat | N/A | 7 | N/A | Nov 12, 2019 | $39.42M |
| Jun 30, 2019 | -$0.21 | -$0.32 | -$0.32 - -$0.29 | +34.38% | Beat | N/A | 4 | N/A | Jul 25, 2019 | $73.61M |
| Mar 31, 2019 | -$2.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 10, 2019 | $35.21M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.07, down 75.0% from the year before. It was -$2.86 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.07 | -75.0% |
| Dec 31, 2024 | $0.28 | +86.7% |
| Dec 31, 2023 | $0.15 | N/A |
| Dec 31, 2022 | -$0.27 | N/A |
| Dec 31, 2021 | -$0.43 | N/A |
| Dec 31, 2020 | -$0.68 | N/A |
| Dec 31, 2019 | -$2.86 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,800 words across 4 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,803 | 4 | |
| 2026Q2 | Jun 30, 2026 | 3,113 | 5 | |
| 2026Q1 | Mar 31, 2026 | 5,205 | 11 | |
| 2025Q4 | Dec 31, 2025 | 5,503 | 12 | |
| 2025Q3 | Sep 30, 2025 | 7,748 | 14 | |
| 2025Q2 | Jun 30, 2025 | 7,718 | 10 | |
| 2025Q1 | Mar 31, 2025 | 8,413 | 16 | |
| 2024Q4 | Dec 31, 2024 | 9,280 | 15 |
2026Q3 Earnings Call
Opening remarks
Stephanie St. Clair SVP of Finance and Investor Relations Good afternoon, and welcome to Health Catalyst's earnings call for the third quarter of 2026. I am Stephanie St. Clair, Senior Vice President of Finance and Investor Relations. With me today are Simeon Kohl, our President and Chief Executive Officer, and Jason Alger, our Chief Financial Officer. A complete disclosure of our results can be found in our press release issued today and our related Form 8-K furnished to the SEC, both of which are available on the Investor Relations section of our website at ir.healthcatalyst.com. A replay of this call will be available afterwards. Today's call includes forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about our financial outlook, expectations for the fourth quarter and full year 2026, client migrations and client retention, future growth and strategic priorities, our ability to strengthen our foundation, our ability to achieve profitable revenue growth and deliver returns to shareholders, our long-term opportunities, retention, bookings, the impact of the Vitalware divestiture, and the general anticipated performance of our business. These forward-looking statements reflect management's views as of today and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to update any forward-looking statement or outlook. Actual results may materially differ. Please see the risk factors in our 2025 Form 10-K filed March 12, 2026, and our third quarter Form 10-Q filed today. We will also discuss non-GAAP measures. Reconciliations to the most comparable GAAP measures are in our press release. Non-GAAP financial information is presented for supplemental purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. We will provide forward-looking guidance for certain non-GAAP measures in this earnings call and are not providing forward-looking guidance for the most directly comparable GAAP guidance measures or reconciliations because some items are not within our control or cannot be reasonably forecasted. Simeon joined us as President and CEO on September 14. With that, I'll turn the call over to him.
Simeon Kohl President and CEO Thank you, Stephanie, and good afternoon, everyone. Earlier this afternoon, we reported third quarter revenue of $56.3 million and adjusted EBITDA of $779,000, both above the high end of our guidance ranges of $55 million–$56 million and $0–$500,000, respectively. Given our performance year to date and with Project Nexus cost reductions on track, we are reaffirming our full-year revenue and adjusted EBITDA outlook. As a reminder, Project Nexus is our strategic initiative designed to fundamentally transform our operating model and deliberately reposition our business.
Frequently Asked Questions About HCAT
When is Health Catalyst's next earnings date?
Health Catalyst's next earnings report is expected for Mar 10, 2027.
Did HCAT beat earnings estimates last quarter?
No. Health Catalyst reported EPS of -$0.08 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 14.29%.
What EPS do analysts expect from HCAT next quarter?
The consensus EPS estimate for Health Catalyst for the quarter ending Dec 31, 2026 is -$0.04 from 7 analysts, with estimates from -$0.05 to -$0.03.
How often does HCAT beat earnings estimates?
Health Catalyst beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -13.49%.
HCAT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors